Hola,
Are you new here?

CIRDinnova

financed

Shifting the limits of resuscitation with CIRD Controlled Integrated Resuscitat...

Shifting the limits of resuscitation with CIRD Controlled Integrated Resuscitation Device Sudden cardiac arrest is one of the most frequent causes of death. But only 3% of the patients survive out-of-hospital resuscitation, and only 18% survive in-hospital resuscitation. Today the time-frame for successful resuscitatio... see more

31/05/2022

UKLFR

3M€

Project Budget: 3M€

Project leader

UNIVERSITAETSKLINIKUM FREIBURG No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

PARTICIPATION DEPralty Sin fecha límite de participación.

Ver 5 Participantes

Financing granted El organismo H2020 notifico la concesión del proyecto The day 2022-05-31

FTIPilot-01-2016: Fast Track to Innovation Pilot Specific Challenge:Innovation is fostered when new ideas can emerge and easily translate into socio-...

I+D

Cerrada does 9 years

0% 78% 100%

characteristics of the participant

Este proyecto no cuenta con búsquedas de partenariado abiertas en este momento.

Private Information

No hay información privada compartida para este proyecto. Habla con el coordinador.

5 Participantes

UKLFR

369.70K€ | Leader

FULLSTEP NETWORKS SA

186.13K€ | participant

ERASMUS MC

198.12K€ | participant

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Project duration: 68 months Date Start: 2016-09-13
End date: 2022-05-31

Project leader

UNIVERSITAETSKLINIKUM FREIBURG No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Project Budget 3M€

participation deadline Sin fecha límite de participación.

Project description Sudden cardiac arrest is one of the most frequent causes of death. But only 3% of the patients survive out-of-hospital resuscitation, and only 18% survive in-hospital resuscitation. Today the time-frame for successful resuscitation is only about 3 to 5 minutes after cardiac arrest. Thereafter, with every minute a rapid decline in survival is observed, tending to zero beyond ten minutes of CPR. For decades no significant improvement of the clinical outcome and no significant scientific progress in resuscitation could be shown! More than 10 years ago a research group led by the international renowned cardiac surgeon Prof F Beyersdorf at the Freiburg University Hospital started intensive clinical R&D to develop a completely new therapeutic concept for resuscitation The new therapeutic concept enables a game changing breakthrough in resuscitation therapy. It is patient-individual and introduces for the first time a controlled, automated and personalized medical therapy in emergency medicine. The designation for the therapy is CARL – Controlled Automated Reperfusion of the whoLe body. To bring this new therapy worldwide into the hospitals and rescue organisations a new start-up company – the ResuSciTec GmbH - has been founded as a Spin-off from the Freiburg University Hospital in 2010. In close collaboration with the Freiburg University Hospital ResuSciTec developed an innovative system of medical devices called CIRD - Controlled Integrated Resuscitation Device. First very promising results from a clinical study in humans are already available. That means ResuSciTec has reached TRL 7. To reach TRL 9 and to start full international commercialisation and wide market take-up a consortium consisting of ResuSciTec as industrial partner and three university hospital in Freiburg (DE), Linz (AT) and Rotterdam (NL) will execute the proposed innovation action.

Conecta tu I+D

Entra hoy

Forgot your password?

Financing

Companies

CTIs/Universidades

Projects

researchers